There is accumulating evidence in the literature indicating that a number of patients with
coronavirus disease 2019 (COVID‑19) may experience a range of neuropsychiatric …

Mapping non-canonical cellular pathways affected by approved medications can accelerate
drug repurposing efforts, which are crucial in situations with a global impact such as the …

Background Fatigue and cognitive complaints are the most frequent persistent symptoms in
patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This …

Cognitive impairment, depression and (mental) fatigue represent the most frequent
neuropsychiatric symptoms of the post-COVID syndrome. Neuroinflammation, oxidative …

Background Depressive and cognitive symptoms like fatigue, loss of energy or sleep
disorders characterise the post-COVID condition. Post-COVID psychosomatic rehabilitation …

Numerous data indicate the presence of cognitive impairment in people who have
undergone COVID-19, often called COVID Fog (CF). This phenomenon persists even 6 …

Background Depression is a common mental disorder and the diagnosis is still based on the
descriptions of symptoms. Biomarkers can reveal disease characteristics for diagnosis …

For 2.5 years we have been facing the coronavirus disease (COVID-19) and its health,
social and economic effects. One of its known consequences is the development of …

Depression is a serious psychological disorder which negatively affects human feelings and
actions. The use of antidepressants is the therapy of choice while treating depression …

Inflammation is an important component of the etiopathology of depression that uses
oxidative and nitrosative stress (O&NS) and elevated inflammatory markers. SARS-CoV-2 …